US news
from24/7 Wall St.
5 days agoBiotech Turnaround: How Moderna Went From Revenue Collapse to YTD Rally Leader
Moderna stock rose 37% YTD in 2026 driven by earnings beats, $2B cost cuts, international manufacturing deals, and pipeline monetization despite regulatory headwinds.